Extended Data Fig. 1: Patient inclusion in endpoint analyses. | Nature Cancer

Extended Data Fig. 1: Patient inclusion in endpoint analyses.

From: Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

Extended Data Fig. 1: Patient inclusion in endpoint analyses.The alternative text for this image may have been generated using AI.

This alluvial diagram depicts the inclusion or exclusion of patients in the analysis of each study endpoint (x-axis). Patients that were treated with pembrolizumab were included in the analysis regarding that pathological complete response (pCR) rates. Patients that were treated with pembrolizumab and underwent surgery were included in the analysis for the relapse-free survival (RFS) rate. Patients that were treated with pembrolizumab and had measurable disease were included in the analysis for clinical response, even if they were not assessed by imaging at 9 weeks.

Back to article page